                         SEQUENCE LISTING

<110>  University of Kentucky Research Foundation
       BRADLEY, Luke H.
       GASH, Don M.
       GERHARDT, Greg A.
 
<120>  ANTI-NEURODEGENERATIVE THERAPEUTIC, METHOD OF MANUFACTURE, AND 
       USE

<130>  085971-597945

<150>  US 62/544,046
<151>  2017-08-11

<160>  11    

<170>  PatentIn version 3.5

<210>  1
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SYNTHESIZED


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  AMIDATION

<400>  1

Leu Ala Pro Ala Glu Asp 
1               5       


<210>  2
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SYNTHESIZED


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  AMIDATION

<400>  2

Glu Ala Pro Phe Glu Asp 
1               5       


<210>  3
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SYNTHESIZED


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  AMIDATION

<400>  3

Leu Ala Pro Tyr Glu Asp 
1               5       


<210>  4
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SYNTHESIZED


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  AMIDATION can either be present or absent

<400>  4

Leu Gly Pro Phe Ser Glu 
1               5       


<210>  5
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SYNTHESIZED

<400>  5

Cys Leu Gly Pro Phe Ser Glu Cys 
1               5               


<210>  6
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SYNTHESIZED


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is D-Ala

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is D-Lys

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  AMIDATION

<400>  6

Trp Xaa Pro Xaa Asp 
1               5   


<210>  7
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SYNTHESIZED


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is D-Glu

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is D-Ala

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  AMIDATION

<400>  7

Xaa Ala Pro Phe Xaa Gly 
1               5       


<210>  8
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SYNTHESIZED


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is deuterated Lys

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is D-Phe

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is deuterated Leu

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  AMIDATION

<400>  8

Glu Xaa Pro Xaa Xaa 
1               5   


<210>  9
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SYNTHESIZED


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is acylated-Leu

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is D-Met

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is deuterated Ser

<400>  9

Xaa Xaa Pro Ala Xaa Phe 
1               5       


<210>  10
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SYNTHESIZED


<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  AMIDATION

<400>  10

Glu Ala Pro Ala Glu 
1               5   


<210>  11
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  SYNTHESIZED


<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  AMIDATION

<400>  11

Glu Ala Pro Ala Glu Asp 
1               5       


